Hu X, Cai H, Zheng L, et al. Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia. Cancer Med. 2020;9:4941--4948. 10.1002/cam4.3140

Xuelian Hu and Haodong Cai contributed equally to this work.

1. INTRODUCTION {#cam43140-sec-0001}
===============

Platelet transfusion is a common treatment conducted in patients with thrombocytopenia to prevent serious hemorrhage. However, not all patients would achieve the expected platelet count increment after platelet transfusion. Platelet transfusion refractoriness (PTR) is defined as the repeated failures to achieve satisfactory responses to platelet transfusions from random donors, and has become an intractable clinical issue that may increase bleeding risks and health‐care costs.[^1^](#cam43140-bib-0001){ref-type="ref"}, [^2^](#cam43140-bib-0002){ref-type="ref"} In patients with cancer, the incidence of PTR differs from 4.8% to 54.7%, according to its distinct definitions and study populations.[^3^](#cam43140-bib-0003){ref-type="ref"}, [^4^](#cam43140-bib-0004){ref-type="ref"}, [^5^](#cam43140-bib-0005){ref-type="ref"}, [^6^](#cam43140-bib-0006){ref-type="ref"} Alloimmunization to HLA antigens and/or human platelet antigens (HPA) is the most common etiology of PTR.[^4^](#cam43140-bib-0004){ref-type="ref"}, [^7^](#cam43140-bib-0007){ref-type="ref"}, [^8^](#cam43140-bib-0008){ref-type="ref"}, [^9^](#cam43140-bib-0009){ref-type="ref"}, [^10^](#cam43140-bib-0010){ref-type="ref"} Anti‐HLA and/or HPA antibodies directly react with donor‐derived platelets and can decrease their functions in vivo.[^11^](#cam43140-bib-0011){ref-type="ref"} Moreover, nonimmune etiologies, including infection, high fever, antibiotics, antifungal medications, heparin, bleeding, splenomegaly, and multiple pregnancies, have also been involved in PTR.[^12^](#cam43140-bib-0012){ref-type="ref"}

Previously, PTR had been reported in AML patients, with risks of severe bleeding and mortality, after they had received intensive chemotherapy or hematopoietic stem cell transplantation.[^3^](#cam43140-bib-0003){ref-type="ref"}, [^10^](#cam43140-bib-0010){ref-type="ref"} However, the underline factors linked with PTR in AML patients are largely unknown. Therefore, to better understand the pathogenesis of PTR in AML, we retrospectively analyzed its clinical and immunologic features in 560 patients who were diagnosed as de novo AML in Tongji Hospital from June 2012 through June 2018.

2. METHODS {#cam43140-sec-0002}
==========

2.1. Definition of platelet transfusion refractoriness {#cam43140-sec-0003}
------------------------------------------------------

PTR is the repeated failure to achieve the desired level of blood platelets in a patient following platelet transfusions. According to the published definitions, PTR in the present study was defined as a posttransfusion platelet increment (PI) that is less than 5 × 10^9^/L after receiving at least two successive daily platelet transfusions.[^2^](#cam43140-bib-0002){ref-type="ref"}, [^13^](#cam43140-bib-0013){ref-type="ref"}, [^14^](#cam43140-bib-0014){ref-type="ref"}

2.2. Patients enrollment {#cam43140-sec-0004}
------------------------

De novo AML patients diagnosed in our department were successively enrolled in this study. Patients with secondary or myelodysplastic syndromes/myeloproliferative neoplasms (MDS/ MPN)‐transformed AML were excluded. Clinical and laboratory features of eligible patients were retrospectively reviewed. Risk assessment and risk stratification‐guided treatment were administrated as previously [^15^](#cam43140-bib-0015){ref-type="ref"}, [^16^](#cam43140-bib-0016){ref-type="ref"}, [^17^](#cam43140-bib-0017){ref-type="ref"} and described in the Supplementary Methods.

This study was approved by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Informed consent was obtained from each individual in accordance with the principles expressed in the Declaration of Helsinki.

2.3. Detection of anti‐HLA class I antibodies {#cam43140-sec-0005}
---------------------------------------------

Whole blood samples were collected from patients with procoagulation tubes when platelet counts were lower than 20 × 10^9^/L after induction chemotherapy. Then serum was separated by centrifugation at 2500 revolutions per minute and frozen at −80℃. The storage time was less than 3 months.

Luminex single antigen beads (SAB) was used in a high‐throughput HLA antibody screening assay (LABScreen Single Antigen HLA Class I, One Lambda) to evaluate the existence of antibodies targeting any donor‐specific HLA class I antigens in the serum, which were the main immunological cause. [^18^](#cam43140-bib-0018){ref-type="ref"}, [^19^](#cam43140-bib-0019){ref-type="ref"} This assay was conducted according to the manufacturer\'s instructions.[^20^](#cam43140-bib-0020){ref-type="ref"}, [^21^](#cam43140-bib-0021){ref-type="ref"}, [^22^](#cam43140-bib-0022){ref-type="ref"} Briefly, 20 μL serum was incubated with 5μL microbeads in a 96‐well V‐bottomed plate in the dark at 25℃ for 30 minutes. After three times of washing, R‐Phycoerythrin‐conjugated goat antihuman IgG antibody was added to the plate for another 30 minutes incubation. The plate was washed for two more times. The single antigen detection beads can identify the following HLA‐I specificities: HLA‐A1, 3, 11, 23‐24, 29‐31, 33‐34, 36, 66, 74, and 80; HLA‐B7, 8, 13, 18, 27, 35, 37‐39, 41, 42, 44‐65, 67, 71‐73, 75‐78, 81, and 82; and HLA‐Cw1, 2, 4‐6, 8‐10, 12, and 14‐18.[^23^](#cam43140-bib-0023){ref-type="ref"} Mean fluorescence intensities (MFI) were acquired using a Luminex analyzer. The results were considered to be positive when MFI was above 5000 and strongly positive when MFI was higher than 10 000.[^24^](#cam43140-bib-0024){ref-type="ref"}, [^25^](#cam43140-bib-0025){ref-type="ref"}

2.4. Statistical analysis {#cam43140-sec-0006}
-------------------------

The patients' characteristics were described by numbers and frequencies for categorical variables, and by medians and interquartile ranges (IQR) for continuous variables. Differences were analyzed using chi‐square test (or Fisher\'s exact test in case of small expected numbers) for categorical variables and Student\'s *t* test for continuous variables. A logistic regression model for multivariate analysis was used to evaluate the risk factors associated with PTR in univariate analysis. *P* values less than .050 (two tailed) were considered to be statistically significant. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 22.0 (IBM) and GraphPad Prism 6.

3. RESULTS {#cam43140-sec-0007}
==========

3.1. Occurrence of PTR in patients with de novo AML {#cam43140-sec-0008}
---------------------------------------------------

From June 2012 through June 2018, a total of 560 patients with de novo AML were screened for eligibility. The median age was 45 years (range, 12‐86) with a male‐to‐female ratio of nearly 4:3. After induction chemotherapy, platelet transfusions were given to patients with active hemorrhage or patients with platelet counts less than 20.0 × 10^9^/L. PTR occurred in 66 (11.8%) patients when they received platelet transfusion from random donors. The median time interval between the conduction of chemotherapy and the onset of PTR was 9.0 days (IQR: 6.0‐17.0 days). The median posttransfusion increments with platelets derived from random donors in PTR patients were 0.5 × 10^9^/L (IQR: −3.0‐3.5 × 10^9^/L). Among the 32 PTR patients who were transfused with HLA‐matched platelets, 10 (31.3%) patients showed responses with a median posttransfusion PI of 26.0 × 10^9^/L (IQR: 17.8‐36.3 × 10^9^/L). And the posttransfusion PI of HLA‐matched platelets was significantly higher compared to nonmatched platelet from random donors (9.6 × 10^9^/L vs −0.7 × 10^9^/L, *P *\< .001, Figure [S1](#cam43140-sup-0001){ref-type="supplementary-material"}). Other management strategies, including intravenous gamma‐globulin and glucocorticoid, were not effective enough to improve platelet response. Severe bleeding events during induction therapy occurred in 5 PTR patients (7.6%), involving gastrointestinal track (n = 2), cerebrum (n = 1), lung (n = 1), and multiple organs (n = 1).

The median age for patients with PTR was 46 years (range, 15‐70) with a female predominance (male‐to‐female ratio, 2:3, *P* = .007). Patients with splenomegaly were more likely to develop PTR (27.3% vs 14.4%, *P* = .007). However, differences in history of transfusion, pregnancy, or autoimmune diseases, the attack of fever or infection, and the use of antibiotics or liposomal amphotericin B were consistent in patients with or without PTR (Table [1](#cam43140-tbl-0001){ref-type="table"}).

###### 

Univariate analysis of PTR in patients with de novo AML

  Factors                                                    PTR               Non‐PTR           *P*‐value
  ---------------------------------------------------------- ----------------- ----------------- -----------
  Total, n (%)                                               66 (11.8)         494 (88.2)        
  Age (y), median (IQR)                                      46 (31.75‐54.0)   45.0 (30‐54.25)   .644
  Gender, n (%)                                                                                  
  Male                                                       27 (40.9)         289 (58.5)        .007
  Female                                                     39 (59.1)         205 (41.5)        
  Pregnancy, n (%)                                                                               
  No                                                         8 (20.5)          31 (15.1)         .400
  Yes                                                        31 (79.5)         174 (84.9)        
  Transfusion history, n (%)                                                                     
  No                                                         49 (76.6)         405 (83.9)        .145
  Yes                                                        15 (23.4)         78 (16.1)         
  NA                                                         2                 11                
  Autoimmune Diseases, n (%)                                                                     
  No                                                         63 (95.5)         487 (98.6)        .102
  Yes                                                        3 (4.5)           7 (1.4)           
  Fever[^a^](#cam43140-note-0003){ref-type="fn"}, n (%)                                          
  No                                                         26 (39.4)         227 (46.0)        .315
  Yes                                                        40 (60.6)         267 (54.0)        
  Infection[^a^](#cam43140-note-0003){ref-type="fn"}, n(%)                                       
  No                                                         59 (89.4)         452 (91.5)        .570
  Yes                                                        7 (10.6)          42 (8.5)          
  Splenomegaly, n (%)                                                                            
  No                                                         48 (72.7)         423 (85.6)        .007
  Yes                                                        18 (27.3)         71 (14.4)         
  Use of antibiotics, n (%)                                                                      
  No                                                         6 (9.1)           32 (6.5)          .433
  Yes                                                        60 (90.9)         462 (93.5)        
  Use of liposomal amphotericin B, n (%)                                                         
  No                                                         61 (92.4)         442 (89.5)        .457
  Yes                                                        5 (7.6)           52 (10.5)         

Abbreviations: AML, acute myeloid leukemia; IQR, interquartile ranges; n, observed number of patients within each treatment group; NA, not available; PTR, platelet transfusion refractoriness.

At diagnose of PTR

John Wiley & Sons, Ltd

3.2. Clinical features of PTR in patients with de novo AML {#cam43140-sec-0009}
----------------------------------------------------------

The clinical features of PTR patients were summarized in Table [2](#cam43140-tbl-0002){ref-type="table"}. At the disease onset, the white blood cell counts, platelet counts, and the percentages of bone marrow blasts were comparable between patients with and without PTR (Table [2](#cam43140-tbl-0002){ref-type="table"}). However, in univariate analysis, PTR occurred predominantly in patients with M4 French‐American‐British (FAB) subtype (*P* = .001), rearrangements of *RUNX1‐RUNX1T1* (*P* = .026) or *CBFB‐MYH11* (*P* \< .001), and c‐*Kit* mutation (*P* = .047), but not inclined to manifest in patients with *NPM1*, *CEBPA*, and *FLT3*‐ITD mutations (Table [2](#cam43140-tbl-0002){ref-type="table"}). Notably, rearrangements of *RUNX1‐RUNX1T1* (OR = 5.025, \[1.762‐14.329\], *P* = .003) or *CBFB‐MYH11* (OR = 20.285, \[4.121‐99.848\], *P* \< .001), which were commonly referred to as core binding factor AML (CBF‐AML), were independently associated with the occurrence of PTR in multivariate analysis (Table [3](#cam43140-tbl-0003){ref-type="table"}).

###### 

Clinical features of PTR in patients with de novo AML

                                                                                               PTR                 Non‐PTR              *P*‐value
  -------------------------------------------------------------------------------------------- ------------------- -------------------- -----------
  Total, n (%)                                                                                 66 (11.8)           494 (88.2)           
  WBC(×10^9^/L), median (IQR)                                                                  11.4 (3.42‐47.20)   10.60 (2.83‐40.15)   .902
  PLT(×10^9^/L), median (IQR)                                                                  31 (22.25‐50.25)    34 (23.0‐54.0)       .141
  Bone marrow blasts (%, IQR), median                                                          77.3 (50.25‐94.5)   73.5 (43.5‐87.0)     .445
  Chromosome aberration, n (%)                                                                                                          
  Normal karyotype                                                                             29/66 (43.9)        255/494 (51.6)       .241
  *RUNX1‐RUNX1T1*                                                                              12/66 (18.2)        46/494 (9.3)         .026
  *CBFB‐MYH11*                                                                                 16/66 (24.2)        18/494 (3.6)         \<.001
  *PML‐RARA*                                                                                   0/66 (0)            48/494 (9.7)         ---
  *MLLT3‐KMT2A*,                                                                               0/66 (0)            3/494 (0.6)          ---
  *BCR‐ABL1*                                                                                   1/66 (1.5)          10/494 (2.0)         1.000
  *MLLT10‐KMT2A*                                                                               0/66 (0)            2/494 (0.4%)         ---
  *MLLT4‐KMT2A*                                                                                0/66 (0)            5/494 (1.0%)         ---
  Gene mutation, n (%)                                                                                                                  
  *NPM1*                                                                                       7/32 (21.9)         45/299 (15.1)        .313
  *CEBPA* (biallelic)                                                                          1/29 (3.4)          19/278 (6.8)         .706
  *FLT3*‐ITD                                                                                   0/29 (0)            52/279 (18.6)        ---
  *c‐Kit*                                                                                      4/28 (14.3)         12/278 (4.3)         .047
  Morphology, n (%)                                                                                                                     
  M0                                                                                           1/66 (1.5)          17/494 (3.4)         .710
  M1                                                                                           7/66 (10.6)         72/494 (14.6)        .384
  M2                                                                                           17/66 (25.8)        113/494 (22.9)       .602
  M3                                                                                           0/66 (0)            48/494 (9.7)         ---
  M4                                                                                           14/66 (21.2)        39/494 (7.9)         .001
  M5                                                                                           16/66 (24.2)        137/494 (27.7)       .550
  Others[^a^](#cam43140-note-0003){ref-type="fn"}, [^a^](#cam43140-note-0005){ref-type="fn"}   11/66 (16.7)        55/494 (11.1)        .190

Abbreviations: AML, acute myeloid leukemia; IQR, interquartile ranges; n, observed number of patients within each treatment group; PTR, platelet transfusion refractoriness.

Others include M6, M7, AML with multilineage dysplasia and AML without available FAB classification.

John Wiley & Sons, Ltd

###### 

Multivariate analysis of PTR in patients with de novo AML

                     Hazard ratio (95% CI)   *P*‐value
  ------------------ ----------------------- -----------
  Female             1.370 (0.585‐3.206)     .468
  Splenomegaly       1.412 (0.535‐3.729)     .486
  M4 FAB subtype     2.243 (0.380‐13.231)    .372
  *c‐Kit* mutation   1.047 (0.255‐4.305)     .949
  *RUNX1‐RUNX1T1*    5.025 (1.762‐14.329)    .003
  *CBFB‐MYH11*       20.285 (4.121‐99.848)   \<.001

Abbreviation: CI, confidence interval.

John Wiley & Sons, Ltd

3.3. PTR frequently manifested in patients with CBF‐AML {#cam43140-sec-0010}
-------------------------------------------------------

PTR manifested in 30.4% (28/92) of the patients who had CBF‐AML, in contrast to 8.1% (38/468) of the others, indicating a strong correlation between PTR and CBF‐AML (*P* \< .001, Figure [1A](#cam43140-fig-0001){ref-type="fig"}, Figure [S2](#cam43140-sup-0001){ref-type="supplementary-material"}A,B). Thus, when received from random donors, the median posttransfusion PI was more significantly reduced in patients with CBF‐AML than in other patients (*P* \< .001, Figure [1B](#cam43140-fig-0001){ref-type="fig"}). Among patients with CBF‐AML, the incidence of PTR (33.3% vs 28.9%, *P* = 1.000, Figure [1C](#cam43140-fig-0001){ref-type="fig"}) and the posttransfusion PI (*P *= .847, Figure [1D](#cam43140-fig-0001){ref-type="fig"}) was comparable in patients with or without *c‐Kit* mutations. Intriguingly, PTR was dramatically developed in patients who achieved 3‐log or more MRD reduction before the second consolidation chemotherapy than in patients who did not achieved it (45.2% vs 17.5%, *P* = .007, Figure [1E](#cam43140-fig-0001){ref-type="fig"}). Accordingly, when received from random donors, the median posttransfusion PI was markedly decreased in patients who had better MRD reduction (*P* \< .001, Figure [1F](#cam43140-fig-0001){ref-type="fig"}).

![Incidence of PTR and posttransfusion PI in patients with CBF‐AML. Patients with CBF‐AML had higher incidence of PTR (A) and lower posttransfusion PI (B) than patients without. Among the patients with CBF‐AML, the incidence of PTR (C) and posttransfusion PI (D) was comparable in patients with or without *c‐Kit* gene mutation. However, higher incidence of PTR (E) and lower posttransfusion PI (F) revealed in patients who further had better MRD reduction (≥3‐log) before the second consolidation chemotherapy. The midline, bottom, and top lines represent the median value, the 25th and the 75th percentiles, respectively. The statistical differences were analyzed by chi‐square test or unpaired two‐tailed student\'s *t* test. CBF‐AML: core binding factor acute myeloid leukemia; MRD: minimal residual disease; NS indicates no significant difference; \*\**P * \< .010; \*\*\**P* \< .001; PI: platelet count increment; PTR: platelet transfusion refractoriness](CAM4-9-4941-g001){#cam43140-fig-0001}

3.4. Outcomes {#cam43140-sec-0011}
-------------

In CBF‐AML patients, there were 6/92 (6.5%) who died in the first month after the commence of induction therapy, which was defined as an early death (Table [S1](#cam43140-sup-0002){ref-type="supplementary-material"}). Among these patients, 5/28 (17.9%) early death occurred in PTR group compared to 1/64 (1.6%) in non‐PTR group (*P *= .009). And early death secondary to bleeding was obviously higher in patients who had PTR (10.7% vs 0). In CBF‐AML patients, there was no statistical difference in overall survival (OS) between PTR and non‐PTR group (*P *= .745, Table [S1](#cam43140-sup-0002){ref-type="supplementary-material"}, Figure [S3](#cam43140-sup-0001){ref-type="supplementary-material"}A). When early death was excluded in both groups, the OS in PTR group showed a tendency of longer survival, but the difference was still not statistically significant (6‐month, 1‐year, 2‐year, and 5‐year OS rates: 100, 94.1, 72.1, and 46.4% in PTR group vs 93.2, 75.6, 65.9, and 40.0% in non‐PTR group, *P *= .337, Table [S1](#cam43140-sup-0002){ref-type="supplementary-material"}, Figure [S3](#cam43140-sup-0001){ref-type="supplementary-material"}B).

In all PTR patients, 7/66 (10.6%) have an early death, including 5/28 (17.9%) in CBF‐AML group and 2/38 (5.3%) in non‐CBF‐AML group (*P *= .125, Table [S2](#cam43140-sup-0002){ref-type="supplementary-material"}). And early death secondary to bleeding was comparable between CBF and non‐CBF‐AML group (10.7% vs 5.3%, *P *= .643). No difference in OS was observed between PTR patients with CBF and non‐CBF‐AML (Figure [S3](#cam43140-sup-0001){ref-type="supplementary-material"}C, *P* = .294), except patients with early death were excluded (Figure [S3](#cam43140-sup-0001){ref-type="supplementary-material"}D, *P* = .040).

3.5. High‐throughput HLA antibody screening {#cam43140-sec-0012}
-------------------------------------------

Using Luminex single antigen beads, we examined anti‐HLA‐I antibodies and screened their HLA specificities in the serum from 133 de novo AML patients. HLA‐I antibodies were detected in 9.0% (12/133) among these patients, including in 62.5% (10/16) of patients with PTR and in 1.7% (2/117) of non‐PTR patients (*P* \< .001, Figure [2A](#cam43140-fig-0002){ref-type="fig"}). Among the 12 patients who had anti‐HLA‐I antibodies, 10 (83.3%) developed PTR. Furthermore, HLA‐I antibodies were detected in 25.0% (5/20) of patients with CBF‐AML, while only in 6.2% (7/113) of the non‐CBF‐AML patients (*P* = .018, Figure [2B](#cam43140-fig-0002){ref-type="fig"}).

![High‐throughput HLA antibody screening in newly diagnosed AML patients. HLA‐I antibodies were detected in 9.0% (12/133) of 133 de novo AML patients. Compared to other patients, antibodies were enriched in patients with PTR (A, 62.5% vs 1.7%, *P* \< .001) or in patients with CBF‐AML (B, 25.0% vs 6.2%, *P* = .018). Moreover, a total of 71 HLA serotypes were identified, with 60.56% (43/71) of the identified epitopes belonging to HLA‐B locus. The epitope distribution of the identified HLA‐I antibodies was illustrated in panel C. The color gradient from blue to red represents the increasing value of MFI from 0 to 15 000.00. Positive cutoff: MFI \> 5000. CBF‐AML: core binding factor acute myeloid leukemia; HLA‐I: human leukocyte antigen class I; MFI: mean fluorescence intensity; \**P* \< .050; \*\*\**P* \< .001; PTR: platelet transfusion refractoriness](CAM4-9-4941-g002){#cam43140-fig-0002}

3.6. Epitope HLA‐B closely related to PTR {#cam43140-sec-0013}
-----------------------------------------

A total of 71 HLA serotypes were identified (Figure [2C](#cam43140-fig-0002){ref-type="fig"}), among which 14 were specific for HLA‐A epitopes, 43 for HLA‐B epitopes, and 14 for HLA‐C epitopes. HLA‐B77 was the most frequently (50.0%, 6/12) identified serotype. HLA‐B35, B45, B47, B52, B56, B62, B75, B76, B78, and B82 were commonly detected as well (41.7%, 5/12) in patients with PTR. However, two HLA‐I antibodies, targeting HLA‐B45 and HLA‐C epitopes, were detected in 2 non‐PTR patients separately (Figure [2C](#cam43140-fig-0002){ref-type="fig"}). HLA‐B45, the solely detected serotype in one non‐PTR patient, was identified with marginal MFI intensity (6684.58). HLA‐C epitope, identified in the other non‐PTR patient, had been previously considered to be expressed on the surface of platelet but not contributing to PTR.[^26^](#cam43140-bib-0026){ref-type="ref"}

4. DISCUSSION {#cam43140-sec-0014}
=============

PTR is a severe complication with increasing risks of bleeding and mortality in patients who received chemotherapy or hematopoietic stem cell transplantation (HSCT). It had been reported in 4.8% (41/897) of adult AML patients who received intensive chemotherapy, and was more frequently occurred in parous women or in patients with extramedullary disease, leukocytopenia, infection, or hemophagocytic syndrome.[^3^](#cam43140-bib-0003){ref-type="ref"} A clinical trial to Reduce Alloimmunization to Platelets (TRAP) conducted in 533 AML patients found that PTR, with an incidence rate of 27%, was associated with positive lymphocytotoxic antibody, heparin administration, fever, bleeding, increasing number of platelet transfusions, increasing weight, at least 2 pregnancies, and male gender. While increasing the dose of platelets transfused or transfusing filtered apheresis platelets could reduce the incidence of PTR.[^4^](#cam43140-bib-0004){ref-type="ref"} Among the patients undergoing HSCT, PTR is also a frequent and complex complication. In a study of 167 transplant patients, patients with PTR had lower infusion dose of CD34^+^ cells, higher usage of antibiotics, presence of anti‐HLA‐I antibodies, or reduced‐intensity conditioning regimen. [^10^](#cam43140-bib-0010){ref-type="ref"} In the present study, PTR was more frequently developed in female patients and in patients with splenomegaly, M4 FAB subtype, *c‐Kit* gene mutation, and *RUNX1‐RUNX1T1* or *CBFB‐MYH11* rearrangements.

CBF‐AML, accounting for approximately 15% of adult AML, is defined by the presence of the fusion genes *RUNX1‐RUNX1T1* or *CBFB‐MYH11*. MRD has been used in clinical practice to identify CBF‐AML patients with higher risk of relapse. Several studies have revealed that a 3‐log or more MRD reduction before the second consolidation is a powerful predictor of lower relapse in patients with CBF‐AML.[^27^](#cam43140-bib-0027){ref-type="ref"}, [^28^](#cam43140-bib-0028){ref-type="ref"}, [^29^](#cam43140-bib-0029){ref-type="ref"} In the present study, patients with CBF‐AML had higher risk to develop HLA‐I antibodies and PTR, suggesting increased autoimmune responses to HLA‐I in patients with CBF‐AML.

Upregulated expression of CD80 and CD86 on blast cells was observed in patients with M4 FAB subtype, about half of them carried *CBFB‐MYH11* rearrangement, and was correlated with prolonged remission after induction therapy. The overexpression of these co‐stimulatory molecules on AML blasts may provoke potent autologous cytotoxic T‐cell (CTL) response, which may mediate immune recognition to both platelets and AML blasts because of the widely expressed HLA molecules on their surface.[^30^](#cam43140-bib-0030){ref-type="ref"}, [^31^](#cam43140-bib-0031){ref-type="ref"}, [^32^](#cam43140-bib-0032){ref-type="ref"} Therefore, platelets can be cleared by the activated CTL posttransfusion through antibody‐dependent or ‐independent manner. And the provoked antileukemia effect may reduce the risk of relapse and prolong the duration of remission after chemotherapy. However, the difference in OS rates between PTR and non‐PTR among CBF‐AML patients did not reach the statistical significance. The survival might be complicated by many other factors and more data with bigger sample size may be able to further clarify the relationship between PTR and CBF‐AML.

Moreover, the significant enrichment of HLA‐I antibodies in our patients with PTR is consistent with the notion that alloimmunization to HLA‐I epitopes is the primary cause of immune‐mediated PTR. HLA‐I molecules are expressed as transmembrane glycoproteins on the surface of platelets and all nucleated cells. And HLA molecules can be endocytosed from the plasma, accounting for another source of HLA‐I epitopes on the surface of platelet. Abundant serum antibodies to HLA‐I epitopes react with the transfused platelets and lead to PTR. Therefore, rituximab, romiplostim, plasma exchange, and intravenous immunoglobulins have been widely used in patients with severe HLA alloimmune PTR, even in patients with myeloid malignancies. [^33^](#cam43140-bib-0033){ref-type="ref"}, [^34^](#cam43140-bib-0034){ref-type="ref"}, [^35^](#cam43140-bib-0035){ref-type="ref"} Moreover, the heavy chain of the HLA‐I molecule is encoded by genes at HLA‐A, HLA‐B, and HLA‐C loci. The most commonly identified epitopes in our patients with PTR belonged to HLA‐B, which suggested that a strategy of "epitope avoidance transfusion" could be used. In this strategy, the actual epitope of HLA antibody should be screened and the transfusion of HLA‐alloimmunized platelets should be avoided. Indeed, improved higher posttransfusion PI had achieved in patients with PTR when transfused with HLA‐matched platelets instead of platelets from random donors.

PTR, an intractable clinical issue in patients with AML, is still full of challenges and demands prompt solutions. We found patients with CBF‐AML had higher risk to develop HLA‐I antibodies and PTR, which depicted novel features of PTR in AML and might provide insights into its efficient managements.
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